A Gounder1, S Gounder1, S A Reid2. 1. National Tuberculosis Program, Ministry of Health, Suva, Fiji. 2. School of Population Health, The University of Queensland, Brisbane, Queensland, Australia.
Abstract
SETTING: All Xpert® MTB/RIF tests performed in the three TB (tuberculosis) treatment centres in Fiji from June 2012 to February 2013. OBJECTIVES: To determine 1) the number of Xpert tests performed in each centre, 2) the association between sputum quality and Xpert results, 3) the agreement of Xpert with acid-fast bacilli (AFB) smear microscopy and TB culture and 4) error rates. DESIGN: Retrospective review of records. RESULTS: A total of 415 Xpert tests were performed in the study period. Mycobacterium tuberculosis was detected in 69 (16.6%) samples. No rifampicin resistance was detected. M. tuberculosis was detected from 60 (18.7%) good-quality sputum samples. A total of 43 (10.4%) errors occurred during this period. M. tuberculosis was detected in 10 (2.9%) smear-negative specimens. There was a substantial and an almost perfect agreement between Xpert and AFB microscopy (κ = 0.793) and culture results (κ = 0.818), respectively. CONCLUSION: Although a good correlation between Xpert and the two tests were shown in the study, Xpert should not replace the routine first-line TB diagnostic tests used in Fiji for reasons related to logistics and sustainability. A further evaluation of the assay's performance is required over a longer time period to gauge its diagnostic value in detecting smear-negative, Xpert-positive cases in Fiji.
SETTING: All Xpert® MTB/RIF tests performed in the three TB (tuberculosis) treatment centres in Fiji from June 2012 to February 2013. OBJECTIVES: To determine 1) the number of Xpert tests performed in each centre, 2) the association between sputum quality and Xpert results, 3) the agreement of Xpert with acid-fast bacilli (AFB) smear microscopy and TB culture and 4) error rates. DESIGN: Retrospective review of records. RESULTS: A total of 415 Xpert tests were performed in the study period. Mycobacterium tuberculosis was detected in 69 (16.6%) samples. No rifampicin resistance was detected. M. tuberculosis was detected from 60 (18.7%) good-quality sputum samples. A total of 43 (10.4%) errors occurred during this period. M. tuberculosis was detected in 10 (2.9%) smear-negative specimens. There was a substantial and an almost perfect agreement between Xpert and AFB microscopy (κ = 0.793) and culture results (κ = 0.818), respectively. CONCLUSION: Although a good correlation between Xpert and the two tests were shown in the study, Xpert should not replace the routine first-line TB diagnostic tests used in Fiji for reasons related to logistics and sustainability. A further evaluation of the assay's performance is required over a longer time period to gauge its diagnostic value in detecting smear-negative, Xpert-positive cases in Fiji.
Authors: Jacob Creswell; Andrew J Codlin; Emmanuel Andre; Mark A Micek; Ahmed Bedru; E Jane Carter; Rajendra-Prasad Yadav; Andrei Mosneaga; Bishwa Rai; Sayera Banu; Miranda Brouwer; Lucie Blok; Suvanand Sahu; Lucica Ditiu Journal: BMC Infect Dis Date: 2014-01-02 Impact factor: 3.090
Authors: Alfred Tonganibeia; Anthony D Harries; Onofre Edwin A Merilles; Tekaibeti Tarataake; Teatao Tiira; Takeieta Kienene Journal: Hawaii J Med Public Health Date: 2018-02
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Collins Timire; Kudakwashe C Takarinda; Anthony D Harries; Herbert Mutunzi; Barbara Manyame-Murwira; Ajay M V Kumar; Charles Sandy Journal: Trans R Soc Trop Med Hyg Date: 2018-06-01 Impact factor: 2.184